Acute Myeloid Leukemia
Acute Myeloid Leukemia
The latest news, research, and perspectives in acute myeloid leukemia (AML). AML, an aggressive blood cancer, is the most common type of acute leukemia in adults and most often develops when myeloid cells that normally develop into the various types of mature blood cells instead form abnormal myeloblasts.
Advertisement
Melissa BadamoAcute Lymphoblastic Leukemia | July 7, 2025
Gaps in coordination and collaboration between primary care and oncology may impact long-term survival outcomes for patients.
Melissa BadamoAcute Myeloid Leukemia | July 1, 2025
Revumenib has received FDA Priority Review with a Prescription Drug User Fee Act target action date of October 25, 2025.
Melissa BadamoAcute Myeloid Leukemia | July 1, 2025
Tuspetinib plus standard of care venetoclax and azacitidine in newly-diagnosed AML showed promising safety and efficacy.
Nichole TuckerAcute Myeloid Leukemia | June 30, 2025
Dr. Amir Fathi discusses oral regimens and future AML therapy trends in this Editor’s Special of The HemOnc Pulse.
Melissa BadamoAcute Myeloid Leukemia | June 24, 2025
SENTI-202, a first-in-class, off-the-shelf, logic-gated CAR-NK cell therapy, is currently being evaluated in a phase 1 trial.
Melissa BadamoAcute Myeloid Leukemia | June 24, 2025
Dr. Bhatnagar shared her research interests on rural disparities in AML and her experience working in a community setting.
Advertisement
Robert ZadottiAcute Myeloid Leukemia | June 23, 2025
Ziftomenib shows strong, lasting responses in R/R NPM1-mutant AML, according to KOMET-001 data shared at EHA 2025.
Sabrina AhleAcute Myeloid Leukemia | June 13, 2025
Talazoparib plus GO shows early signs of activity in relapsed/refractory AML, warranting further study, per EHA 2025 poster.
Melissa BadamoMyelodysplastic Syndromes | June 10, 2025
Azacitidine plus valproic acid is a safe and feasible maintenance regimen for patients with high-risk AML and MDS after HSCT.
Rahul Banerjee, MD, FACPAcute Myeloid Leukemia | June 30, 2025
Experts discuss early detection in myeloid malignancies, from current challenges to future innovations.
Melissa BadamoAcute Myeloid Leukemia | May 19, 2025
ADP-heptose in the intestines of older individuals accelerates the expansion of pre-leukemic blood cells.
Melissa BadamoAcute Lymphoblastic Leukemia | May 16, 2025
Studies have shown that oncologists are leaving the workforce at increasing rates in association with growing workloads.
Nichole TuckerAcute Myeloid Leukemia | May 27, 2025
Sankalp Arora, MBBS, a second-year fellow at MD Anderson, presented data on FLT3 inhibitors in AML at the HemOnc Pulse Live.
Andrew MorenoAcute Myeloid Leukemia | May 14, 2025
Results from the phase 1b study suggest venetoclax plus modified chemotherapy is an effective and well-tolerated approach.
Melissa BadamoAcute Myeloid Leukemia | May 13, 2025
Tuspetinib in combination with venetoclax and azacitidine showed promising clinical safety and antileukemic activity in AML.
Andrew MorenoAcute Myeloid Leukemia | May 9, 2025
Presented preclinical model data show significant efficacy against AML cell lines with FLT3, KMT2A, NPM1, and TP53 mutations.
Melissa BadamoAcute Lymphoblastic Leukemia | May 8, 2025
LucyRx’s pharmacy network includes Northwestern Medicine Specialty Pharmacy, Dana Farber Cancer Institute, and more..
Melissa BadamoAcute Myeloid Leukemia | May 6, 2025
Mice treated with CLK3 TCR9-T cells had a significantly lower tumor burden than those who received control treatments.
Kelly S. Chien, MDAcute Myeloid Leukemia | May 6, 2025
Kelly Chien, MD, discusses how disparities in access to care, resources, and molecular testing impact outcomes in AML.
Melissa BadamoAcute Myeloid Leukemia | April 29, 2025
CR1-02 was well-tolerated and led to stable disease in patients with relapsed or refractory AML.
Advertisement
Advertisement